Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) G-CSF Biosimilars Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global G-CSF Biosimilars Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 Human Growth Hormone
      • 1.3.3 Erythropoietin
      • 1.3.4 Monoclonal Antibodies
      • 1.3.5 Insulin
      • 1.3.6 Interferon
      • 1.3.7 Granulocyte-Colony Stimulating Factor
    • 1.4 Market Segment by Application
      • 1.4.1 Global G-CSF Biosimilars Market Share by Application (2019-2025)
      • 1.4.2 Blood Disorders
      • 1.4.3 Oncology Diseases
      • 1.4.4 Chronic And Autoimmune Diseases
      • 1.4.5 Growth Hormone Deficiencies
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global G-CSF Biosimilars Market Size
      • 2.1.1 Global G-CSF Biosimilars Revenue 2014-2025
      • 2.1.2 Global G-CSF Biosimilars Sales 2014-2025
    • 2.2 G-CSF Biosimilars Growth Rate by Regions
      • 2.2.1 Global G-CSF Biosimilars Sales by Regions 2014-2019
      • 2.2.2 Global G-CSF Biosimilars Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 G-CSF Biosimilars Sales by Manufacturers
      • 3.1.1 G-CSF Biosimilars Sales by Manufacturers 2014-2019
      • 3.1.2 G-CSF Biosimilars Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 G-CSF Biosimilars Revenue by Manufacturers (2014-2019)
      • 3.2.2 G-CSF Biosimilars Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global G-CSF Biosimilars Market Concentration Ratio (CR5 and HHI)
    • 3.3 G-CSF Biosimilars Price by Manufacturers
    • 3.4 Key Manufacturers G-CSF Biosimilars Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into G-CSF Biosimilars Market
    • 3.6 Key Manufacturers G-CSF Biosimilars Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 Human Growth Hormone Sales and Revenue (2014-2019)
      • 4.1.2 Erythropoietin Sales and Revenue (2014-2019)
      • 4.1.3 Monoclonal Antibodies Sales and Revenue (2014-2019)
      • 4.1.4 Insulin Sales and Revenue (2014-2019)
      • 4.1.5 Interferon Sales and Revenue (2014-2019)
      • 4.1.6 Granulocyte-Colony Stimulating Factor Sales and Revenue (2014-2019)
    • 4.2 Global G-CSF Biosimilars Sales Market Share by Type
    • 4.3 Global G-CSF Biosimilars Revenue Market Share by Type
    • 4.4 G-CSF Biosimilars Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global G-CSF Biosimilars Sales by Application

    6 United States

    • 6.1 United States G-CSF Biosimilars Breakdown Data by Company
    • 6.2 United States G-CSF Biosimilars Breakdown Data by Type
    • 6.3 United States G-CSF Biosimilars Breakdown Data by Application

    7 European Union

    • 7.1 European Union G-CSF Biosimilars Breakdown Data by Company
    • 7.2 European Union G-CSF Biosimilars Breakdown Data by Type
    • 7.3 European Union G-CSF Biosimilars Breakdown Data by Application

    8 China

    • 8.1 China G-CSF Biosimilars Breakdown Data by Company
    • 8.2 China G-CSF Biosimilars Breakdown Data by Type
    • 8.3 China G-CSF Biosimilars Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World G-CSF Biosimilars Breakdown Data by Company
    • 9.2 Rest of World G-CSF Biosimilars Breakdown Data by Type
    • 9.3 Rest of World G-CSF Biosimilars Breakdown Data by Application
    • 9.4 Rest of World G-CSF Biosimilars Breakdown Data by Countries
      • 9.4.1 Rest of World G-CSF Biosimilars Sales by Countries
      • 9.4.2 Rest of World G-CSF Biosimilars Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 Pfizer
      • 10.1.1 Pfizer Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of G-CSF Biosimilars
      • 10.1.4 G-CSF Biosimilars Product Introduction
      • 10.1.5 Pfizer Recent Development
    • 10.2 Novartis
      • 10.2.1 Novartis Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of G-CSF Biosimilars
      • 10.2.4 G-CSF Biosimilars Product Introduction
      • 10.2.5 Novartis Recent Development
    • 10.3 Roche
      • 10.3.1 Roche Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of G-CSF Biosimilars
      • 10.3.4 G-CSF Biosimilars Product Introduction
      • 10.3.5 Roche Recent Development
    • 10.4 Merck & Co.
      • 10.4.1 Merck & Co. Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of G-CSF Biosimilars
      • 10.4.4 G-CSF Biosimilars Product Introduction
      • 10.4.5 Merck & Co. Recent Development
    • 10.5 Sanofi
      • 10.5.1 Sanofi Company Details
      • 10.5.2 Company Description and Business Overview
      • 10.5.3 Sales, Revenue and Market Share of G-CSF Biosimilars
      • 10.5.4 G-CSF Biosimilars Product Introduction
      • 10.5.5 Sanofi Recent Development
    • 10.6 Johnson & Johnson
      • 10.6.1 Johnson & Johnson Company Details
      • 10.6.2 Company Description and Business Overview
      • 10.6.3 Sales, Revenue and Market Share of G-CSF Biosimilars
      • 10.6.4 G-CSF Biosimilars Product Introduction
      • 10.6.5 Johnson & Johnson Recent Development
    • 10.7 Gilead Science
      • 10.7.1 Gilead Science Company Details
      • 10.7.2 Company Description and Business Overview
      • 10.7.3 Sales, Revenue and Market Share of G-CSF Biosimilars
      • 10.7.4 G-CSF Biosimilars Product Introduction
      • 10.7.5 Gilead Science Recent Development
    • 10.8 GlaxoSmithKline
      • 10.8.1 GlaxoSmithKline Company Details
      • 10.8.2 Company Description and Business Overview
      • 10.8.3 Sales, Revenue and Market Share of G-CSF Biosimilars
      • 10.8.4 G-CSF Biosimilars Product Introduction
      • 10.8.5 GlaxoSmithKline Recent Development
    • 10.9 AbbVie
      • 10.9.1 AbbVie Company Details
      • 10.9.2 Company Description and Business Overview
      • 10.9.3 Sales, Revenue and Market Share of G-CSF Biosimilars
      • 10.9.4 G-CSF Biosimilars Product Introduction
      • 10.9.5 AbbVie Recent Development
    • 10.10 Amgen
      • 10.10.1 Amgen Company Details
      • 10.10.2 Company Description and Business Overview
      • 10.10.3 Sales, Revenue and Market Share of G-CSF Biosimilars
      • 10.10.4 G-CSF Biosimilars Product Introduction
      • 10.10.5 Amgen Recent Development
    • 10.11 AstraZeneca
    • 10.12 Bayer

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 G-CSF Biosimilars Sales Channels
      • 11.2.2 G-CSF Biosimilars Distributors
    • 11.3 G-CSF Biosimilars Customers

    12 Market Forecast

    • 12.1 Global G-CSF Biosimilars Sales and Revenue Forecast 2019-2025
    • 12.2 Global G-CSF Biosimilars Sales Forecast by Type
    • 12.3 Global G-CSF Biosimilars Sales Forecast by Application
    • 12.4 G-CSF Biosimilars Forecast by Regions
      • 12.4.1 Global G-CSF Biosimilars Sales Forecast by Regions 2019-2025
      • 12.4.2 Global G-CSF Biosimilars Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      Granulocyte colony-stimulating factor (G-CSF) is a glycoprotein containing 174 amino acids with a molecular weight of about 20000.
      The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World. Annual estimates and forecasts are provided for the period 2018 through 2025. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.
      This report analyzes the worldwide markets for G-CSF Biosimilars in US$ by the following Product Segments: Human growth hormone, Erythropoietin, Monoclonal antibodies, Insulin, Interferon, Granulocyte-Colony Stimulating Factor
      Company profiles are primarily based on public domain information including company
      Merck & Co.
      Sanofi
      Johnson & Johnson
      Gilead Science
      GlaxoSmithKline
      AbbVie
      Amgen
      AstraZeneca
      Bayer
      Pfizer
      Novartis
      Roche

      In 2019, the market size of G-CSF Biosimilars is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for G-CSF Biosimilars.

      This report studies the global market size of G-CSF Biosimilars, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the G-CSF Biosimilars sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      Pfizer
      Novartis
      Roche
      Merck & Co.
      Sanofi
      Johnson & Johnson
      Gilead Science
      GlaxoSmithKline
      AbbVie
      Amgen
      AstraZeneca
      Bayer

      Market Segment by Product Type
      Human Growth Hormone
      Erythropoietin
      Monoclonal Antibodies
      Insulin
      Interferon
      Granulocyte-Colony Stimulating Factor

      Market Segment by Application
      Blood Disorders
      Oncology Diseases
      Chronic And Autoimmune Diseases
      Growth Hormone Deficiencies

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the G-CSF Biosimilars status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key G-CSF Biosimilars manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of G-CSF Biosimilars are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now